Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life.
about
Chemotherapy for advanced, recurrent or metastatic endometrial carcinomaChemotherapy and supportive care versus supportive care alone for advanced non-small cell lung cancerChemotherapy for advanced, recurrent or metastatic endometrial carcinomaChemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trialsMaintenance chemotherapy for advanced non-small-cell lung cancer: new life for an old idea50 Years of progress in the systemic therapy of non-small cell lung cancerPhase II trial of sequential gefitinib after minor response or partial response to chemotherapy in Chinese patients with advanced non-small-cell lung cancer.Phase III randomized trial comparing moderate-dose cisplatin to combined cisplatin and carboplatin in addition to mitomycin and ifosfamide in patients with stage IV non-small-cell lung cancer.Combination of gemcitabine and cisplatin as first-line therapy in advanced non-small-cell lung cancerComparison of vinorelbine-Cisplatin with gemcitabine-Cisplatin in patients with advanced non-small cell lung cancer.First-line bevacizumab, cisplatin and vinorelbine plus maintenance bevacizumab in advanced non-squamous non-small cell lung cancer chemo-naïve patients.Is there still a role for mitomycin-based combination chemotherapy in treating patients with nonsmall cell lung cancer? A single institution experience.Eligibility of patients with advanced non-small cell lung cancer for phase III chemotherapy trialsAssociation of nutritional status and serum albumin levels with development of toxicity in patients with advanced non-small cell lung cancer treated with paclitaxel-cisplatin chemotherapy: a prospective study.Genotypes and haplotypes of the VEGF gene and survival in locally advanced non-small cell lung cancer patients treated with chemoradiotherapy.Chemotherapy for non-small cell lung cancer.Immediate versus delayed palliative thoracic radiotherapy in patients with unresectable locally advanced non-small cell lung cancer and minimal thoracic symptoms: randomised controlled trialChemotherapy plus best supportive care versus best supportive care in patients with non-small cell lung cancer: a meta-analysis of randomized controlled trialsThe case for the introduction of new chemotherapy agents in the treatment of advanced non small cell lung cancer in the wake of the findings of The National Institute of Clinical Excellence (NICE).Platinum drugs in the treatment of non-small-cell lung cancerLung cancer--where are we today? Current advances in staging and nonsurgical treatment.Polymorphisms of homologous recombination genes and clinical outcomes of non-small cell lung cancer patients treated with definitive radiotherapy.Advanced NSCLC: from cytotoxic systemic chemotherapy to molecularly targeted therapy.Lung cancer. 4: chemotherapy for non-small cell lung cancer: the end of the beginning.Lung cancer 5: state of the art radiotherapy for lung cancerLung cancer 7: management of lung cancer in elderly patients.Chemotherapy of lung cancer: A global perspective of the role of ifosfamideA Bayesian dose-finding design for phase I/II clinical trials with nonignorable dropoutsChemotherapy versus supportive care in advanced non-small cell lung cancer: improved survival without detriment to quality of life.Evolutionary modeling of combination treatment strategies to overcome resistance to tyrosine kinase inhibitors in non-small cell lung cancerThe role of epidermal growth factor receptor in advanced non-small cell lung carcinoma.Second-line chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC).Sequence polymorphisms of the mitochondrial displacement loop and outcome of non-small cell lung cancer.Quality of life in advanced non-small cell lung cancer patients receiving palliative chemotherapy: A meta-analysis of randomized controlled trialsState of the art in therapy for non-small cell lung cancer.Safety profile of platinum-based chemotherapy in the treatment of advanced non-small cell lung cancer in elderly patients.Gemcitabine and carboplatin: is this the best combination for non-small cell lung cancer?Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer.A randomised phase II trial of docetaxel vs docetaxel and irinotecan in patients with stage IIIb-IV non-small-cell lung cancer who failed first-line treatment.Survival of patients with non-small cell lung cancer without treatment: a systematic review and meta-analysis.
P2860
Q24201586-E8143085-8066-48DA-8E9F-4F17248E81DFQ24235422-C87DE1CF-DD41-4339-B398-09C7C9E335C8Q24246360-D96FB6D3-F5B6-4951-91E8-747BFC9C4684Q24643017-45530AFB-ED99-44EF-B9EE-7F5EF647854FQ27011282-BC5876EE-F9DB-42CB-8DA5-EBB9D0A262E1Q27014978-318CB267-DDC8-43E0-9142-02A7D017B83EQ33266837-2A9D248B-1D50-4461-86F1-EAED1960F4BEQ33334597-EB8D64A7-36B3-44A9-9568-7C27E5F8C935Q33389157-DE150BEE-C161-43DE-BDA0-E3BC49360673Q33393287-B9C504A5-ADD1-4AEF-B080-1C1BD2F851B1Q33401434-7F16B247-A99D-4C8C-9566-F410E11F4A3BQ33403648-256FCF5B-5FEE-4EEE-AE12-44DDB059C8A8Q33436415-80E3FBEF-D83D-4A0D-A8E6-9B4604A08F1BQ33532808-9A4FA37E-2C50-4A93-A96F-118653CB0BFBQ33659635-FBF90CC0-7090-4380-B363-FCCB125281DBQ33910132-CE4C44A8-A391-4857-B518-58C715EFC690Q33932354-DD5DEF03-1E68-4041-BD2A-146ED48E9247Q34650404-443BAD05-9180-4653-B212-CE96A2B2F870Q34791240-FB1E182E-17A2-4B5F-A193-F4695888EA82Q34954760-0E0C2CFF-2EA4-4F42-A99D-99DC10258DA3Q34982142-0608BA3A-F228-4398-9458-B61CAE8DECC6Q35007346-D0268D3B-0949-47D4-9390-1CBE2730A9D8Q35089127-C4D38F32-DEAD-4DA4-9376-AF23D8F4DAD3Q35096015-0DB7115A-84FA-4A08-896C-6D59EBE0ECACQ35120111-E703C585-441D-42E6-BA69-ADE85AC39DC9Q35186819-EDDBAF37-B285-416E-9A77-815A435394D9Q35200383-6E209A97-ADD4-4E88-8D78-8B8A2D908861Q35328870-79EB4DD3-356F-4470-81E4-42F0B909C320Q35536245-CBADB076-1C3A-4EF9-8A20-B98B314AB995Q35591358-D0BAFE56-4799-477C-9783-9A48182EE458Q35597610-6773958A-A3C3-45B9-A033-0F573790D31FQ36028725-C7E6243B-5F41-4643-BD48-F7D59D37783FQ36224392-7B67FAE5-3C54-4AE0-83FC-01357D880786Q36224556-2D82997A-64DA-4136-A57C-71F60C379546Q36271949-0363E8ED-252A-4847-95FD-92BC6DC1DC63Q36299985-50F7DAAA-0B84-4901-9D43-9DADA5284DE6Q36381261-A38CFD1B-D449-4CEC-B2A8-553BD2DA932FQ36612331-4303B356-BD60-45BE-9C81-5C615C19FEA1Q36615741-BBBCDB60-7392-4E60-83D4-750735E51949Q36630997-F142AB1D-C08B-4016-A040-2F2B791C1CE6
P2860
Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life.
description
1999 nî lūn-bûn
@nan
1999年の論文
@ja
1999年学术文章
@wuu
1999年学术文章
@zh
1999年学术文章
@zh-cn
1999年学术文章
@zh-hans
1999年学术文章
@zh-my
1999年学术文章
@zh-sg
1999年學術文章
@yue
1999年學術文章
@zh-hant
name
Mitomycin, ifosfamide, and cis ...... survival and quality of life.
@en
Mitomycin, ifosfamide, and cis ...... survival and quality of life.
@nl
type
label
Mitomycin, ifosfamide, and cis ...... survival and quality of life.
@en
Mitomycin, ifosfamide, and cis ...... survival and quality of life.
@nl
prefLabel
Mitomycin, ifosfamide, and cis ...... survival and quality of life.
@en
Mitomycin, ifosfamide, and cis ...... survival and quality of life.
@nl
P2093
P1476
Mitomycin, ifosfamide, and cis ...... survival and quality of life.
@en
P2093
A D Chetiyawardana
C K Connolly
C M Woodroffe
M H Cullen
P304
P356
10.1200/JCO.1999.17.10.3188
P407
P577
1999-10-01T00:00:00Z